Navigation Links
Schering-Plough Announces Closing of Planned Divestiture of Selected Animal Health Products
Date:7/1/2008

KENILWORTH, N.J., July 2 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP) today announced the successful closing of its previously announced transaction with Virbac, S.A. to divest animal health products from selected franchises. These divestments were requested by the European Commission as part of its October 2007 clearance of the acquisition of Organon BioSciences N.V.

In Europe, Virbac acquired products from the endocrine, mastitis and sulphonamide franchises of Intervet/Schering-Plough Animal Health. The agreement does not affect the marketing of these products in other global markets. In a second agreement with Virbac that has also closed successfully, Virbac acquired Prosolvin, a product from the fertility range, for worldwide use. That acquisition also satisfied a request by the South African Competition Commission in connection with Schering-Plough's 2007 acquisition of Organon BioSciences N.V. Virbac has acquired these assets for an aggregate euro 28 million in cash.

By separate agreement announced in April, products from Intervet/Schering-Plough Animal Health's parasiticide, swine E. coli vaccine, ruminant clostridia vaccine, equine influenza vaccine, ruminant neonatal vaccine, anti-inflammatory, companion animal/insulin and companion animal/euthanasia, and rabies vaccine franchises will be acquired by a subsidiary of Pfizer. The closing of that transaction is expected to take place later this year following receipt of necessary regulatory approvals.

Schering-Plough is an innovation-driven, science-centered global health care company. Through its own biopharmaceutical research and collaborations with partners, Schering-Plough creates therapies that help save and improve lives around the world. The company applies its research-and-development platform to human prescription and consumer products as well as to animal health products. Schering-Plough's vision is to "Earn Trust, Every Day" with the doctors, patients, customers and other stakeholders served by its colleagues around the world. The company is based in Kenilworth, N.J., and its Web site is http://www.schering-plough.com.


'/>"/>
SOURCE Schering-Plough Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Schering-Plough Declares Quarterly Dividends on Common Shares and 2007 Mandatory Convertible Preferred Stock
2. Schering-Plough Schedules Conference Call and Webcast for 2008 Second Quarter Earnings
3. Schering-Plough Appoints Janet M. Barth Vice President, Investor Relations
4. Schering-Plough Schedules Webcast for Annual Meeting of Shareholders
5. Intervet/Schering-Plough Animal Health Outlines Strength of the Combination
6. Schering-Plough/MERCK Pharmaceuticals Receives Not-Approvable Letter from FDA for Loratadine/Montelukast
7. Schering-Plough CEO Buys $2 Million in Common Shares
8. Schering-Plough Announces Planned Divestiture of Select Animal Health Products in Europe
9. Schering-Plough Reports Financial Results for First Quarter of 2008
10. Schering-Plough Schedules Conference Call and Webcast for 2008 First Quarter Earnings
11. Schering-Plough Launches Productivity Transformation Program To Confront New Challenges
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/17/2017)... , Feb. 17, 2017  If only ... tumor had a mutation-conferring resistance to chemotherapy, thousands ... genomics research has focused on finding these mutations ... even from circulating tumor DNA in blood — ... oncology therapeutics. Unfortunately, however, detecting these ...
(Date:2/16/2017)... , ... February 16, 2017 , ... EIT Digital ... primarily aimed at the agricultural industry. Pilot studies are about to get under way ... IoT, Big Data and 5G innovations. The concept is expected to be transferred eventually ...
(Date:2/16/2017)... MENLO PARK, Calif. and ... -- Longitude Capital, a private investment firm focused on ... today announced the promotion of Josh Richardson ... Richardson focuses on investments in biotechnology companies.  He ... and has played important roles in Longitude,s investments ...
(Date:2/16/2017)... Feb. 16, 2017 Research and ... Biology: Global Markets" report to their offering. ... ... genes, biobrick parts, delivery plasmids, chassis organisms, synthetic cells, ... assembly, genome editing, bioinformatics and specialty media) and enabled ...
Breaking Biology Technology:
(Date:1/30/2017)... --  Invitae Corporation (NYSE: NVTA ), ... announced that it will report its fourth quarter and ... Monday, February 13, 2017, and Invitae,s management team will ... Eastern / 1:45 p.m. Pacific. During ... results, guidance, and recent developments and will spend the ...
(Date:1/24/2017)... Jan. 24, 2017 Biopharm Reports has ... laboratory use of nuclear magnetic resonance spectroscopy (NMR). ... and profiled current practices, developments, trends and end-user ... as growth and opportunities. These areas include growth ... instruments, needs and innovation requirements, hyphenated NMR techniques, ...
(Date:1/19/2017)... PUNE, India , January 19, 2017 ... Sensor Market, Opportunities and Forecast, 2014 - 2022," the global biometric sensor ... of 9.6% from 2016 to 2022. In 2015, Asia-Pacific ... for both public and private sectors. Continue Reading ... ...
Breaking Biology News(10 mins):